




Study Summary

Multi-national Phase 3 Study

Further Cardiovascular **OU**tcomes **R**esearch with PCSK9 **I**nhibition in Subjects with **E**levated **R**isk)

Repatha® **OU**tcomes **S**tudy funded by Amgen who manufacture the drug.

The trial explored whether Repatha® (evolocumab) reduces the risk of heart-related events in patients with heart disease.



Repatha® (evolocumab) increases the 'good cholesterol' in the blood by stopping the liver removing it and also lowers 'bad cholesterol'.



FOURIER was a **double-blind, randomized, placebo-controlled trial** in 27,500 patients who had either an MI, an ischemic stroke or symptomatic peripheral artery disease and poor cholesterol results on statins.

Patients were randomized to inject Repatha (140 mg every two weeks or 420 mg monthly) or placebo. The study continued until at least 1,630 patients experienced a key MACE (major adverse cardiac event) – cardiovascular death, MI or stroke.

Text adapted from summary prepared by Amgen: <http://www.amgen.com>